Pleiotropic Effects of the Protease-Activated Receptor 1 (PAR1) Inhibitor, Vorapaxar, on Atherosclerosis and Vascular Inflammation.
Julian FriebelEileen MoritzMarco WitkowskiKai JakobsElisabeth Tamara SträsslerAndrea DörnerDaniel SteffensMarianna PucciniStella LammelRainer GlaubenFranziska NowakNicolle KränkelArash HaghikiaVerena MoosHeinz-Peter SchutheissStephan B FelixUlf LandmesserBernhard H RauchUrsula RauchPublished in: Cells (2021)
PAR1 inhibition with vorapaxar may be effective in reducing residual thrombo-inflammatory event risk in patients with atherosclerosis independent of its effect on platelets.